ANI Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ANI Pharmaceuticals generated cash of $118,959,000, which is more than the previous year. Cash used in financing activities reached the amount of $67,439,000 last year. Net change in cash is therefore $167,887,000.
Cash Flow
| 2014 | 22.03M | -35.75M | 171.65M |
|---|---|---|---|
| 2015 | 17.26M | -32.68M | 1.06M |
| 2016 | 27.47M | -154.06M | -729K |
| 2017 | 39.41M | -107.99M | 72.35M |
| 2018 | 67.07M | -27.37M | -27.81M |
| 2019 | 45.63M | -27.54M | 1.25M |
| 2020 | 15.26M | -68.32M | -1.43M |
| 2021 | 3.32M | -105.48M | 194.59M |
| 2022 | -31.20M | -15.73M | -5.12M |
| 2023 | 118.95M | -18.51M | 67.43M |
ANIP Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 53.23M | 105.30M | 12.86M | 67.36M | 48.02M | 36.15M | 32.36M | 154.68M | 169.03M | 11.10M |
Operating activities | ||||||||||
Net income | 18.77M | -47.89M | -42.60M | -22.54M | 6.09M | 15.49M | -1.07M | 3.93M | 15.37M | 28.74M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 59.79M | 59.65M | 47.25M | 44.63M | 44.61M | 33.74M | 27.92M | 22.34M | 6.9M | 3.87M |
Stock-based compensation expense | 20.65M | 14.59M | 10.48M | 12.93M | 9.21M | 0 | 6.09M | 6.06M | 3.85M | 3.42M |
| Deferred income tax benefit | 20.65M | 14.59M | 10.48M | 12.93M | 9.21M | 0 | 6.09M | 6.06M | 3.85M | 3.42M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 3.35M | -36.91M | -5.54M | -23.66M | -7.28M | -4.74M | -12.89M | -23.96M | -4.63M | -4.78M |
Inventories | -5.84M | -23.62M | 3.22M | -2.75M | -7.66M | -379K | 5.35M | -1.93M | -5.86M | -3.46M |
Accounts payable | 7.55M | 5.03M | 10.16M | -2.29M | 5.03M | 3.46M | 3K | 1.07M | -1.02M | 225K |
Cash generated by operating activities | 118.95M | -31.20M | 3.32M | 15.26M | 45.63M | 67.07M | 39.41M | 27.47M | 17.26M | 22.03M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.00M | 0 | 0 |
Investments In Property Plant And Equipment | -8.86M | -16.45M | -23.63M | -68.32M | -27.54M | -10.91M | -107.99M | -149.06M | -32.68M | -35.75M |
Acquisitions Net | 0 | -33K | -84.49M | 0 | 0 | -16.46M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -18.51M | -15.73M | -105.48M | -68.32M | -27.54M | -27.37M | -107.99M | -154.06M | -32.68M | -35.75M |
Financing activities | ||||||||||
Common Stock Issued | 80.55M | 0 | 75M | 618K | 0 | 0 | 0 | 0 | 0 | 46.68M |
Payments for dividends | -1.62M | -1.62M | -190K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -4.98M | -1.95M | -890K | -1.52M | -1.03M | -659K | -259K | -2.62M | -113K | 0 |
Repayments of term debt | -3M | -3M | -211.01M | -15.53M | 115.29M | -2.81M | 75M | 0 | 0 | -138.24M |
Cash used in financing activities | 67.43M | -5.12M | 194.59M | -1.43M | 1.25M | -27.81M | 72.35M | -729K | 1.06M | 171.65M |
Net Change In Cash | 167.88M | -52.06M | 92.43M | -54.49M | 19.33M | 11.87M | 3.78M | -127.31M | -14.35M | 157.93M |
Cash at end of period | 221.12M | 53.23M | 105.30M | 12.86M | 67.36M | 48.02M | 36.15M | 27.36M | 154.68M | 169.03M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |